Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
alpha-2 adrenergic agonist |
| gptkbp:ATCCode |
S01EA05
|
| gptkbp:brand |
gptkb:Mirvaso
Alphagan |
| gptkbp:CASNumber |
70359-46-5
|
| gptkbp:developedBy |
gptkb:Allergan
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C11H10BrN5
|
| https://www.w3.org/2000/01/rdf-schema#label |
brimonidine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
increases uveoscleral outflow
reduces aqueous humor production |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
B3 (Australia) |
| gptkbp:routeOfAdministration |
topical
ophthalmic |
| gptkbp:sideEffect |
fatigue
dry mouth eye irritation allergic conjunctivitis |
| gptkbp:synonym |
brimonidine tartrate
|
| gptkbp:usedFor |
glaucoma
ocular hypertension facial erythema of rosacea |
| gptkbp:bfsParent |
gptkb:alpha-2_adrenergic_receptor
gptkb:Mirvaso |
| gptkbp:bfsLayer |
8
|